- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03077854
Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
A Single-Blind Randomized Trial of Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Locally Advanced Non-Small Cell and Small Cell Lung Cancer
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Feng-Ming Hsu, MD
- Phone Number: 67061 +886-2-23123456
- Email: hsufengming@ntuh.gov.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Feng-Ming Hsu, MD
- Phone Number: 67061 +886-2-23123456
- Email: hsufengming@ntuh.gov.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with a histologic diagnosis of non-small cell carcinoma or small cell carcinoma of lung
- Locally advanced stage III A or III B lung carcinoma according to American Joint Committee on Cancer (AJCC) 7th edition or highly selected patients with oligo-metastatic disease amendable for thoracic radiotherapy with curative intent
- Not undergoing radical surgical resection
- Patients do not have prior radiotherapy to the thorax
- Age ≥ 20 years
- Karnofsky performance status (KPS) ≥ 60%.
- Women of childbearing potential and male participants must practice adequate contraception
- Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent
Exclusion criteria:
- Prior radiotherapy to thorax
- Unable to receive assigned radiation dose due to normal lung constraint
- Inability to attend full course of radiotherapy or follow-up visits
- Presence of metastatic disease. Patients who present with oligo-metastatic disease where all metastases have been ablated (with surgery or radiotherapy) or in complete remission after systemic therapy are candidates if they are receiving radiotherapy to the thoracic disease with curative intent
Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:
- Uncontrolled active infection requiring intravenous antibiotics at the time of registration
- Transmural myocardial infarction ≤ 6 months prior to registration.
- Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration.
- Life-threatening uncontrolled clinically significant cardiac arrhythmias.
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- Uncontrolled psychiatric disorder.
- Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic.
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Functional Lung Avoidance-TRT
Functional Lung Avoidance Thoracic Radiotherapy The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable |
|
Active Comparator: Standard-TRT
Standard Thoracic Radiotherapy The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging |
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The pulmonary quality of life at 3 months post-radiotherapy
Time Frame: Change from Baseline Functional Assessment of Cancer Therapy-Lung Cancer Subscale at 3 months
|
Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS)
|
Change from Baseline Functional Assessment of Cancer Therapy-Lung Cancer Subscale at 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Number of participant alive
|
From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Changes of pulmonary function test post-radiotherapy
Time Frame: At baseline, 3, 6, 12 months, and annually until year 5 post-radiotherapy
|
Screening spirometry, diffusion capacity of lung for carbon monoxide
|
At baseline, 3, 6, 12 months, and annually until year 5 post-radiotherapy
|
Patient reported outcome (Quality of Life questionnaire by Functional Assessment of Cancer Therapy)
Time Frame: At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
|
Functional Assessment of Cancer Therapy-Lung
|
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
|
Patient reported outcome (Quality of Life questionnaire by EORTC Core)
Time Frame: At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
|
EORTC Quality of Life-Core 30 questionnaire module
|
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
|
Patient reported outcome (Quality of Life questionnaire by EORTC Lung cancer)
Time Frame: At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
|
EORTC Quality of Life questionnaire -Lung cancer 13
|
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
|
Acute toxicity
Time Frame: From date of radiotherapy until 90 days after radiotherapy starts
|
Common Toxicity Criteria for Adverse Events version 4
|
From date of radiotherapy until 90 days after radiotherapy starts
|
Late toxicity
Time Frame: 90 days after radiotherapy starts until the date of death from any cause, up to 60 months
|
Common Toxicity Criteria for Adverse Events version 4
|
90 days after radiotherapy starts until the date of death from any cause, up to 60 months
|
Progression free survival
Time Frame: From date of enrollment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Number of participant without disease progression
|
From date of enrollment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum biomarkers in association with radiation pneumonitis
Time Frame: At baseline, 1, 2, 3, 4, 6 months post-radiotherapy
|
Tumor necrosis factor-alpha, Transforming growth factor-beta concentration measured by ELISA
|
At baseline, 1, 2, 3, 4, 6 months post-radiotherapy
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201604007RINA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage III Non-small Cell Lung Cancer
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)UnknownStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage III Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Mesothelin PositiveUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyActive, not recruitingStage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIC Lung Cancer AJCC v8 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7United States
Clinical Trials on Functional Lung Avoidance Thoracic Radiotherapy
-
Lawson Health Research InstituteTerminatedNon-small Cell Lung CancerCanada
-
Kaohsiung Medical University Chung-Ho Memorial...UnknownBrain Metastases | Neurocognitive FunctionTaiwan
-
Shanghai Cancer Hospital, ChinaUnknownThoracic NeoplasmsChina
-
University Hospital, ToulouseCompletedCOVID-19 | Acute Respiratory Failure | Triage | Lung Ultrasound | CT ScanFrance
-
Centre hospitalier de l'Université de Montréal...Varian Medical SystemsCompletedLung Cancer | Radiation Pneumonitis | Lung Function DecreasedCanada
-
AHS Cancer Control AlbertaCross Cancer InstituteCompletedExtensive Stage Small Cel Lung CancerCanada
-
Swedish Lung Cancer Study GroupRecruitingQuality of Life | Non Small Cell Lung Cancer | Radiotherapy | Stage IV Non-small Cell Lung CancerSweden
-
Danish Pain Research CenterDOLORisk Consortium; Aarhus University HospitalCompletedChronic Neuropathic Pain, Postoperative | Chronic Pain, Postoperative | Chronic Chemotherapy-induced Neuropathic Pain | Chronic Chemotherapy-induced Pain | Chronic Chemotherapy-induced Peripheral NeuropathyDenmark
-
Beijing Chao Yang HospitalRecruiting
-
yu gengshengRecruitingCarcinoma, Non-Small-Cell Lung | Stage IV | Thoracic RadiotherapyChina